김종광
#대장암#위암#식도암#췌장암#간암#담도암#위장관기질종양
|
학력
1993년 경북대학교 의과대학 졸업 (의학학사)
2001년 경북대학교 의과대학 대학원 석사
2004년 경북대학교 의과대학 대학원 박사 (내과학)
2001년 경북대학교 의과대학 대학원 석사
2004년 경북대학교 의과대학 대학원 박사 (내과학)
경력
2003년 M.D Anderson Cancer Center
2017년-현재 칠곡경북대학교병원 기획조정실장
2017년-현재 칠곡경북대학교병원 기획조정실장
논문
1. Byung Woog Kang, Jong Gwang Kim, In Hee Lee, Han Ik Bae, An Na Seo. Clinical significance of tumor-infiltrating lymphocytes for gastric cancer in the era of immunology. World J Gastrointest Oncol 2017;9:293-299.
2. Park S, Kang BW, Lee SJ, Yoon S, Chae YS, Kim JG, Lee KH, Koh SA, Song HS, Park KU, Kim JY, Heo MH, Ryoo HM, Cho YY, Jo J, Lee JL, Lee SA.. Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer. Cancer Chemother Pharmacol 2017;80:187-193.
3. Baek DW, Kang BW, Hwang S, Kim JG, Seo AN, Bae HI, Kwon OK, Lee SS, Chung HY, Yu W. Clinical Significance of p53 Protein Expression, Beta-catenin Expression and HER2 Expression for Epstein-Barr Virus-associated Gastric Cancer. Chonnam Med J 2017;53:140-146.
4. Kim JY, DO YR, Song HS, Cho YY, Ryoo HM, Bae SH, Kim JG, Chae YS, Kang BW, Baek JH, Kim MK, Lee KH, Park K. Multicenter Phase II Clinical Trial of Genexol-PM® with Gemcitabine in Advanced Biliary Tract Cancer. Anticancer Research 2017;37:1467-1473.
5. Lee IH, Hwang S, Lee SJ, Kang BW, Baek D, Kim HJ, Park SY, Park JS, Choi GS, Kim JC, Cho SH, Kim JG. Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer. Anticancer Research 2017;37:1459-1465.
6. Kang BW, Choi Y, Kwon OK, Lee SS, Chung HY, Yu W, Bae HI, Seo AN, Kang H, Lee SK, Jeon SW, Hur K, Kim JG. High level of viral microRNA-BART20-5p expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. Oncotarget 2017
7. Lee SJ, Kang BW, Kim JG, Jung JH, Lee J, Kim WW, Park HY, Jeong JH, Jeong JY, Park JY, Park JH, Chae YS. AQP5 Variants Affect Tumoral Expression of AQP5 and Survival in Patients with Early Breast Cancer. Oncology 2017;92:153-160.
8. Lee IH, Lee SJ, Kang BW, Chae YS, Baek D, Hwang S, Kim HJ, Park SY, Park JS, Choi GS, Kim JC, Kim JG. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer. Cancer Chemother Pharmacol 2016;78:1263-1267.
9. Kang BW, Jeon HS, Chae YS, Lee SJ, Park JS, Choi GS, Kim JG. Impact of Genetic Variation in MicroRNA-binding Site on Susceptibility to Colorectal Cancer. Anticancer Res 2016;36:3353-61.
10. Yoon S, Kang BW, Park SY, Kim HJ, Park JS, Choi GS, Kim JG. Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. J Cancer Res Clin Oncol 2016;142:1775-1780.
11. Kang BW, Kwon OK, Chung HY, Yu W, Kim JG. Taxanes in the Treatment of Advanced Gastric Cancer. Molecules 2016;21:pii:E651
12. Park SY, Choi GS, Park JS, Kim HJ, Yang CS, Kim JG, Kang BW. Efficacy of Early Postoperative Intraperitoneal Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer: A Case-Control Study from a Single Center. Ann Surg Oncol 2016;23:2266-73.
13. Lee MA, Cho EK, Oh SY, Ahn JB, Lee JY, Thomas B, Jung H, Kim JG. Clinical Practices and Outcomes on CINV Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian ChemoTherapy InduCed Emesis burden of illness Study. Cancer Res Treat 2016;48:1420-1428.
14. Lee SJ, Kang BW, Chae YS, Kim HJ, Park SY, Park JS, Choi GS, Kim JG. Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer. Ann Surg Oncol 2016;23(3):894-9.
15. Kang BW, Seo AN, Yoon S, Bae HI, Jeon SW, Kwon OK, Chung HY, Yu W, Kim JG. Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer. Ann Oncol 2016;27:494-501.
16. Yoon S, Kim JG, Seo AN, Park SY, Kim HJ, Park JS, Choi GS, Jeong JY, Jun do Y, Yoon GS, Kang BW. Clinical Implication of Serine Metabolism-Associated Enzymes in Colon Cancer. Oncology. 2015;89(6):351-359.
17. Kang BW, Kim JG, Park H, Park BE, Jeon SW, Bae HI, Kwon OK, Chung HY, Yu W. Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer. Chonnam Med J 2015;51:81-85.
18. Lee M, Son M, Ryu E, Shin YS, Kim JG, Kang BW, Cho H, Kang H. Quercetin-induced apoptosis prevents EBV infection. Oncotarget 2015;6:12603-126024.
19. Kim JY, Ryoo HM, Bae SH, Kang BW, Chae YS, Yoon S, Baek JH, Kim MK, Lee KH, Lee SA, Song HS, Kim JG. Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer. Anticancer Res. 2015 Jun;35(6):3531-6.
20. Kang S, Chae YS, Lee SJ, Kang BW, Kim JG, Kim WW, Jung JH, Park HY, Jeong JH, Jeong JY, Park JY. Aquaporin 3 Expression Predicts Survival in Patients with HER2-positive Early Breast Cancer. Anticancer Res 2015;35:2775-2782.
21. Lee SJ, Kang BW, Chae YS, Cho SH, Kim HJ, Park SY, Park JS, Choi GS, Kim JG. Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemother Pharmacol 2015:76:29-34.
22. Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR, Han HS, Chung IJ, Song EK, Lee KH, Kang SY, Kang YK. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer 2015;51:482-488.
23. Kang BW, Kim JG, Lee SJ, Chae YS, Jeong JY, Yoon GS, Park SY, Kim HJ, Park JS, Choi GS, Jeong JY. Expression of Aquaporin-1, Aquaporin-3, and Aquaporin-5 Correlates with Nodal Metastasis in Colon Cancer. Oncology 2015;88:369-376.
24. Kang BW, Jeon HS, Chae YS, Lee SJ, Park JY, Choi JE, Park JS, Choi GS, Kim JG. Association between GWAS-Identified Genetic Variations and Disease Prognosis for Patients with Colorectal Cancer. PLoS One 2015;23:10:e0119649.
25. Shin HC, Seo J, Kang BW, Moon JH, Chae YS, Lee SJ, Lee YJ, Han S, Seo SK, Kim JG, Sohn SK, Park TI. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. Korean J Inter Med 2014;6:785-792.
26. Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, Dalen J, Jung H, Liu YP, Burke TA, Keefe DM. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer 2015;23:263-272.
27. Lee SJ, Seo JW, Chae YS, Kim JG, Kang BW, Kim WW, Jung JH, Park HY, Jeong JY, Park JY. Genetic polymorphism of miR-196a as a prognostic biomarker for early breast cancer. Anticancer Res 2014;34:2943-9.
28. Kim JG, Chae YS, Lee SJ, Kang BW, Park JY, Lee EJ, Jeon HS, Park JS, Choi GS. Genetic variation in microRNA-binding site and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 2015;141:35-41.
29. Lee SJ, Kang BW, Chae YS, Kim HJ, Park SY, Choi GS, Jeon HS, Lee WK, Kim JG. Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with cholorectal cancer. Ann Surg Oncol 2014;4:634-639.
30. Kang BW, Kim JG, Kwon OK, Chung HY, Yu W. Non-platinum-based chemotherapy for treatment of advanced gastric cancer. 5-fluorouracil, taxanes, and irinotecan. World J Gastroenterol 2014;20:5396-5402.
(외 123개의 논문)
2. Park S, Kang BW, Lee SJ, Yoon S, Chae YS, Kim JG, Lee KH, Koh SA, Song HS, Park KU, Kim JY, Heo MH, Ryoo HM, Cho YY, Jo J, Lee JL, Lee SA.. Clinical significance of systemic chemotherapy after curative resection of metachronous pulmonary metastases from colorectal cancer. Cancer Chemother Pharmacol 2017;80:187-193.
3. Baek DW, Kang BW, Hwang S, Kim JG, Seo AN, Bae HI, Kwon OK, Lee SS, Chung HY, Yu W. Clinical Significance of p53 Protein Expression, Beta-catenin Expression and HER2 Expression for Epstein-Barr Virus-associated Gastric Cancer. Chonnam Med J 2017;53:140-146.
4. Kim JY, DO YR, Song HS, Cho YY, Ryoo HM, Bae SH, Kim JG, Chae YS, Kang BW, Baek JH, Kim MK, Lee KH, Park K. Multicenter Phase II Clinical Trial of Genexol-PM® with Gemcitabine in Advanced Biliary Tract Cancer. Anticancer Research 2017;37:1467-1473.
5. Lee IH, Hwang S, Lee SJ, Kang BW, Baek D, Kim HJ, Park SY, Park JS, Choi GS, Kim JC, Cho SH, Kim JG. Systemic Inflammatory Response After Preoperative Chemoradiotherapy Can Affect Oncologic Outcomes in Locally Advanced Rectal Cancer. Anticancer Research 2017;37:1459-1465.
6. Kang BW, Choi Y, Kwon OK, Lee SS, Chung HY, Yu W, Bae HI, Seo AN, Kang H, Lee SK, Jeon SW, Hur K, Kim JG. High level of viral microRNA-BART20-5p expression is associated with worse survival of patients with Epstein-Barr virus-associated gastric cancer. Oncotarget 2017
7. Lee SJ, Kang BW, Kim JG, Jung JH, Lee J, Kim WW, Park HY, Jeong JH, Jeong JY, Park JY, Park JH, Chae YS. AQP5 Variants Affect Tumoral Expression of AQP5 and Survival in Patients with Early Breast Cancer. Oncology 2017;92:153-160.
8. Lee IH, Lee SJ, Kang BW, Chae YS, Baek D, Hwang S, Kim HJ, Park SY, Park JS, Choi GS, Kim JC, Kim JG. Pilot study of FMC (5-fluorouracil, mitomycin C, and cisplatin) with radiotherapy for patients with anal cancer. Cancer Chemother Pharmacol 2016;78:1263-1267.
9. Kang BW, Jeon HS, Chae YS, Lee SJ, Park JS, Choi GS, Kim JG. Impact of Genetic Variation in MicroRNA-binding Site on Susceptibility to Colorectal Cancer. Anticancer Res 2016;36:3353-61.
10. Yoon S, Kang BW, Park SY, Kim HJ, Park JS, Choi GS, Kim JG. Prognostic relevance of genetic variants involved in immune checkpoints in patients with colorectal cancer. J Cancer Res Clin Oncol 2016;142:1775-1780.
11. Kang BW, Kwon OK, Chung HY, Yu W, Kim JG. Taxanes in the Treatment of Advanced Gastric Cancer. Molecules 2016;21:pii:E651
12. Park SY, Choi GS, Park JS, Kim HJ, Yang CS, Kim JG, Kang BW. Efficacy of Early Postoperative Intraperitoneal Chemotherapy After Complete Surgical Resection of Peritoneal Metastasis from Colorectal Cancer: A Case-Control Study from a Single Center. Ann Surg Oncol 2016;23:2266-73.
13. Lee MA, Cho EK, Oh SY, Ahn JB, Lee JY, Thomas B, Jung H, Kim JG. Clinical Practices and Outcomes on CINV Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian ChemoTherapy InduCed Emesis burden of illness Study. Cancer Res Treat 2016;48:1420-1428.
14. Lee SJ, Kang BW, Chae YS, Kim HJ, Park SY, Park JS, Choi GS, Kim JG. Pilot Study of Neoadjuvant Chemoradiotherapy with Three Cycles of 5-Fluorouracil Plus Leucovorin for Treatment of Locally Advanced Rectal Cancer. Ann Surg Oncol 2016;23(3):894-9.
15. Kang BW, Seo AN, Yoon S, Bae HI, Jeon SW, Kwon OK, Chung HY, Yu W, Kim JG. Prognostic value of tumor-infiltrating lymphocytes in Epstein-Barr virus-associated gastric cancer. Ann Oncol 2016;27:494-501.
16. Yoon S, Kim JG, Seo AN, Park SY, Kim HJ, Park JS, Choi GS, Jeong JY, Jun do Y, Yoon GS, Kang BW. Clinical Implication of Serine Metabolism-Associated Enzymes in Colon Cancer. Oncology. 2015;89(6):351-359.
17. Kang BW, Kim JG, Park H, Park BE, Jeon SW, Bae HI, Kwon OK, Chung HY, Yu W. Clinical Significance of MET Gene Copy Number in Patients with Curatively Resected Gastric Cancer. Chonnam Med J 2015;51:81-85.
18. Lee M, Son M, Ryu E, Shin YS, Kim JG, Kang BW, Cho H, Kang H. Quercetin-induced apoptosis prevents EBV infection. Oncotarget 2015;6:12603-126024.
19. Kim JY, Ryoo HM, Bae SH, Kang BW, Chae YS, Yoon S, Baek JH, Kim MK, Lee KH, Lee SA, Song HS, Kim JG. Multi-center Randomized Phase II Study of Weekly Docetaxel Versus Weekly Docetaxel-plus-Oxaliplatin as a Second-line Chemotherapy for Patients with Advanced Gastric Cancer. Anticancer Res. 2015 Jun;35(6):3531-6.
20. Kang S, Chae YS, Lee SJ, Kang BW, Kim JG, Kim WW, Jung JH, Park HY, Jeong JH, Jeong JY, Park JY. Aquaporin 3 Expression Predicts Survival in Patients with HER2-positive Early Breast Cancer. Anticancer Res 2015;35:2775-2782.
21. Lee SJ, Kang BW, Chae YS, Cho SH, Kim HJ, Park SY, Park JS, Choi GS, Kim JG. Pilot study of modified FOLFOX6 adjuvant chemotherapy for high-risk rectal cancer treated with neoadjuvant chemoradiotherapy. Cancer Chemother Pharmacol 2015:76:29-34.
22. Ryu MH, Yoo C, Kim JG, Ryoo BY, Park YS, Park SR, Han HS, Chung IJ, Song EK, Lee KH, Kang SY, Kang YK. Multicenter phase II study of trastuzumab in combination with capecitabine and oxaliplatin for advanced gastric cancer. Eur J Cancer 2015;51:482-488.
23. Kang BW, Kim JG, Lee SJ, Chae YS, Jeong JY, Yoon GS, Park SY, Kim HJ, Park JS, Choi GS, Jeong JY. Expression of Aquaporin-1, Aquaporin-3, and Aquaporin-5 Correlates with Nodal Metastasis in Colon Cancer. Oncology 2015;88:369-376.
24. Kang BW, Jeon HS, Chae YS, Lee SJ, Park JY, Choi JE, Park JS, Choi GS, Kim JG. Association between GWAS-Identified Genetic Variations and Disease Prognosis for Patients with Colorectal Cancer. PLoS One 2015;23:10:e0119649.
25. Shin HC, Seo J, Kang BW, Moon JH, Chae YS, Lee SJ, Lee YJ, Han S, Seo SK, Kim JG, Sohn SK, Park TI. Clinical significance of nuclear factor κB and chemokine receptor CXCR4 expression in patients with diffuse large B-cell lymphoma who received rituximab-based therapy. Korean J Inter Med 2014;6:785-792.
26. Hsieh RK, Chan A, Kim HK, Yu S, Kim JG, Lee MA, Dalen J, Jung H, Liu YP, Burke TA, Keefe DM. Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. Support Care Cancer 2015;23:263-272.
27. Lee SJ, Seo JW, Chae YS, Kim JG, Kang BW, Kim WW, Jung JH, Park HY, Jeong JY, Park JY. Genetic polymorphism of miR-196a as a prognostic biomarker for early breast cancer. Anticancer Res 2014;34:2943-9.
28. Kim JG, Chae YS, Lee SJ, Kang BW, Park JY, Lee EJ, Jeon HS, Park JS, Choi GS. Genetic variation in microRNA-binding site and prognosis of patients with colorectal cancer. J Cancer Res Clin Oncol 2015;141:35-41.
29. Lee SJ, Kang BW, Chae YS, Kim HJ, Park SY, Choi GS, Jeon HS, Lee WK, Kim JG. Genetic variations in STK11, PRKAA1, and TSC1 associated with prognosis for patients with cholorectal cancer. Ann Surg Oncol 2014;4:634-639.
30. Kang BW, Kim JG, Kwon OK, Chung HY, Yu W. Non-platinum-based chemotherapy for treatment of advanced gastric cancer. 5-fluorouracil, taxanes, and irinotecan. World J Gastroenterol 2014;20:5396-5402.
(외 123개의 논문)
저서
저서 내용이 없습니다.
보도자료
[암과의 동행] 경북대병원 종양내과 김종광 교수 “지나친 채식위주 식단은 영양불균형·합병증 초래”
http://news.kmib.co.kr/article/view.asp?arcid=0922849951&code=14130000&cp=nv
[Health] 김종광 칠곡경북대병원 혈액종양내과 교수 "대장암 표적치료제 효과적…유전자검사 반드시 받아야"
https://www.hankyung.com/society/article/2014092462921
http://news.kmib.co.kr/article/view.asp?arcid=0922849951&code=14130000&cp=nv
[Health] 김종광 칠곡경북대병원 혈액종양내과 교수 "대장암 표적치료제 효과적…유전자검사 반드시 받아야"
https://www.hankyung.com/society/article/2014092462921
포스팅
포스팅 내용이 없습니다.
영상자료
칠곡경북대학교병원 김종광 교수 대구MBC 메디컬 약손 [항암치료]
https://blog.naver.com/knumc2114/222012769861
https://blog.naver.com/knumc2114/222012769861
발표자료
발표자료 내용이 없습니다.